Halozyme Therapeutics

HALO · NASDAQ

$124.37+$1.87 (+1.53%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $122.50

Latest news

NewsOct 14, 11:39 AM ETPiero Cingari
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
NewsOct 14, 10:02 AM ETAvi Kapoor
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
Press releaseOct 7, 8:30 AM ETPRNewswire
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
Press releaseOct 6, 4:05 PM ETPRNewswire
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology
Press releaseSep 30, 4:05 PM ETPRNewswire
Halozyme Announces Appointment of Jim Daly to its Board of Directors
Press releaseSep 17, 11:20 PM ETPRNewswire
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Press releaseSep 16, 4:30 PM ETPRNewswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Press releaseSep 2, 8:30 AM ETPRNewswire
Halozyme to Participate at Upcoming Investor Conferences
Press releaseAug 18, 4:01 PM ETPRNewswire
Halozyme Appoints Dannielle Appelhans to its Board of Directors
NewsAug 6, 4:05 PM ET
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate
Press releaseAug 6, 4:01 PM ETPRNewswire
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Press releaseJul 23, 8:30 AM ETPRNewswire
Halozyme to Report Second Quarter 2026 Financial and Operating Results
Press releaseJul 20, 8:00 AM ETPRNewswire
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Press releaseJun 30, 4:02 PM ETPRNewswire
Halozyme Appoints David Ramsay as President Drug Delivery
Press releaseJun 15, 6:00 AM ETPRNewswire
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
NewsMay 11, 4:03 PM ET
Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate
Press releaseMay 11, 4:01 PM ETPRNewswire
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
Press releaseMay 7, 9:00 AM ETPRNewswire
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
Press releaseMay 6, 8:00 AM ETPRNewswire
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Press releaseApr 30, 4:30 PM ETPRNewswire
Halozyme to Report First Quarter 2026 Financial and Operating Results
Press releaseApr 30, 8:00 AM ETPRNewswire
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
Press releaseApr 7, 8:00 AM ETPRNewswire
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
Press releaseMar 12, 8:30 AM ETPRNewswire
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Press releaseMar 6, 8:00 AM ETPRNewswire
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Press releaseFeb 25, 8:30 AM ETPRNewswire
Halozyme to Participate in Upcoming Investor Conferences
NewsFeb 19, 1:00 PM ET
Demystifying Halozyme Therapeutics: Insights From 4 Analyst Reviews
NewsFeb 17, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsFeb 17, 4:04 PM ET
Halozyme Therapeutics Earnings Report: Q4 Overview
NewsFeb 17, 4:02 PM ET
Halozyme Therapeutics Q4 Adj. EPS $(0.24) Misses $2.20 Estimate, Sales $451.767M Beat $437.977M Estimate
Press releaseFeb 17, 4:01 PM ETPRNewswire
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
NewsFeb 16, 12:01 PM ET
Earnings Preview: Halozyme Therapeutics
Press releaseFeb 10, 4:05 PM ETPRNewswire
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
NewsJan 28, 6:43 AM ET
Halozyme Therapeutics Acquires Surf Bio For Total Consideration Of Up To $400M
Press releaseJan 28, 6:30 AM ETPRNewswire
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Press releaseJan 28, 6:30 AM ETPRNewswire
/C O R R E C T I O N -- Nootropics Depot/
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsMay 28, 11:00 AM ET
Price Over Earnings Overview: Halozyme Therapeutics
NewsMay 24, 8:01 AM ETChris Katje
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
NewsMay 13, 1:11 PM ETAvi Kapoor
Crude Oil Gains 3%; US Inflation Eases In April

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today

Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Halozyme Announces Appointment of Jim Daly to its Board of Directors

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Appoints Dannielle Appelhans to its Board of Directors

Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Appoints David Ramsay as President Drug Delivery

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate

HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Earnings Scheduled For May 11, 2026

Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Halozyme to Report First Quarter 2026 Financial and Operating Results

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

Halozyme to Participate in Upcoming Investor Conferences

Demystifying Halozyme Therapeutics: Insights From 4 Analyst Reviews

12 Health Care Stocks Moving In Tuesday's After-Market Session

Halozyme Therapeutics Earnings Report: Q4 Overview

Halozyme Therapeutics Q4 Adj. EPS $(0.24) Misses $2.20 Estimate, Sales $451.767M Beat $437.977M Estimate

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Earnings Preview: Halozyme Therapeutics

Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

Halozyme Therapeutics Acquires Surf Bio For Total Consideration Of Up To $400M

Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

/C O R R E C T I O N -- Nootropics Depot/

Earnings Scheduled For August 5, 2025

Price Over Earnings Overview: Halozyme Therapeutics

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Crude Oil Gains 3%; US Inflation Eases In April